These findings are underlined by a recent randomized trial which assessed IL-6 levels as a primary outcome in patients with ALI and ARDS and found no survival benefit in these patients as a secondary (but not powered for) outcome measure [11]. The gene discussed is IL6; the disease is acute respiratory distress syndrome.